{"entity":{"id":"celularity","kind":"company","name":"Celularity","aka":["Celularity Inc"],"tldr":"Celularity makes cell therapies and other products from the placenta after birth. It developed a ready-made natural killer cell therapy that was tested in acute myeloid leukaemia and glioblastoma, but the company now describes its main focus as diseases of ageing rather than cancer.","summary":"Celularity, listed on Nasdaq as CELU and based in Florham Park, New Jersey, develops placenta-derived cell therapies and biomaterials. Its own timeline traces it to Anthrogenesis, founded in 1998, which merged with Celgene in 2002; Celularity was spun out in 2017 and became a public company in 2021. Its NK cell platform page describes CYNK-001 as a cryopreserved, allogeneic, off-the-shelf natural killer cell therapy and lists clinical programmes in newly diagnosed acute myeloid leukaemia (NCT04310592) and glioblastoma (NCT04489420), as well as multiple myeloma and COVID-19. The current pipeline page leads with unmodified placental mesenchymal-like cells for Crohn's disease, diabetic foot ulcers and facioscapulohumeral muscular dystrophy, and lists an early-stage engineered T cell programme for solid tumours. The company describes its targets as age-related diseases.","asOf":"2026-11-03","links":[{"label":"Official website","url":"https://celularity.com/"},{"label":"About and timeline","url":"https://celularity.com/about/"},{"label":"NK cell platform","url":"https://celularity.com/nk-cell-platform/"},{"label":"Pipeline","url":"https://celularity.com/pipeline/"},{"label":"SEC filings","url":"https://celularity.com/sec-filings/"}],"tags":[],"related":[],"cancers":["aml","glioblastoma","multiple-myeloma"],"sections":["cell-therapy"],"technologies":["nk-cell-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founded is the 2017 spin-out year on the company's timeline; its predecessor Anthrogenesis dates from 1998. The status and results of the CYNK-001 trials were not checked, and those trials are not yet records in OnCo. The solid tumour T cell programme has no named indication or phase on the pipeline page. HQ is the business address in SEC EDGAR."],"hq":"Florham Park, NJ","country":"US","companyType":"cell-therapy","website":"https://celularity.com/","ticker":"CELU","founded":2017,"stage":"public","investors":[],"funding":[]},"route":"/companies/celularity/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"nk-cell-therapy","kind":"technology","name":"NK cell therapy and CAR-NK","route":"/technologies/nk-cell-therapy/"}]}}